Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status

Bittner, M; Llaurado Fernandez, M; Hoenisch, J; Leung, YY; Kim, H; Wong, NKY; Pishas, KI; Cheasley, D; Cowley, KJ; Simpson, KJ; Lin, YY; Volik, S; Le Bihan, S; Collins, CC; K&#246;bel, M; Carey, MS

Author(s): Bittner, M; Llaurado Fernandez, M; Hoenisch, J; Leung, YY; Kim, H; Wong, NKY; Pishas, KI; Cheasley, D; Cowley, KJ; Simpson, KJ; Lin, YY; Volik, S; Le Bihan, S; Collins, CC; Köbel, M; Carey, MS;
Details: Publication Year 2026-02-12,Volume 27,Issue #4,Page 1774
Journal Title: International Journal of Molecular Sciences
Publication Type: Research article
Abstract: Low-grade serous ovarian carcinoma (LGSOC) usually presents in advanced stages and is associated with a high mortality rate. Clinical trials targeting the MAPK and cell cycle pathways in LGSOC have shown promising results for its treatment, however there is a need to improve efficacy and define predictive biomarkers to guide patient selection for treatment using these agents. We therefore evaluated cell cycle protein expression by immunohistochemistry (IHC) in 186 LGSOC cases, and evaluated the efficacy of the MEK inhibitor, trametinib, in combination with the CDK4/6 inhibitor, palbociclib, in preclinical models of LGSOC. Abnormal p16 expression was observed in 20% of primary and 46% of recurrent tumors, and it was associated with poorer survival (log-rank p = 0.005). Notably, cell lines with increased sensitivity to trametinib were more likely to harbor mutations in KRAS or NF1 and displayed low pRb levels. Palbociclib showed limited efficacy in vitro; however, the combination of palbociclib and trametinib treatment produced synergistic antiproliferative effects in KRAS/NF1-wild-type cell lines, which displayed higher pRb levels. Acquired drug resistance was linked to increased cyclin D1/E1 expression. This study confirms abnormal p16 IHC as a negative prognostic marker in LGSOC and establishes key determinants of sensitivity to CDK4/6 inhibitor-based therapy.
Publisher: MDPI
Keywords: Mapk; low-grade serous ovarian carcinoma; ovarian cancer; p16/CDKN2A; palbociclib; targeted therapies; trametinib
Department(s): Laboratory Research
Publisher's Version: https://doi.org/10.3390/ijms27041774
Open Access at Publisher's Site: https://doi.org/10.3390/ijms27041774
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2026-03-05 03:10:33

Last Modified: 2026-03-05 03:10:47